Rho GTPase-mediated pathways in autoimmune arthritis
Rho GTPase 介导的自身免疫性关节炎通路
基本信息
- 批准号:8770006
- 负责人:
- 金额:$ 43.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-12-01 至 2015-11-30
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsArthritisAutoantigensAutoimmune ResponsesAutoimmunityBindingBinding ProteinsBiologicalBiologyCD4 Positive T LymphocytesCardiovascular DiseasesCell NucleusCellsClinical TrialsClone CellsDevelopmentDiseaseEffectivenessEventExhibitsGenesGoalsGuanine Nucleotide Exchange FactorsIRF4 geneImmune responseInterleukin-17Kidney DiseasesKnowledgeMediatingModelingMolecularMusNamesPathway interactionsPhosphorylationPlayProductionProtein IsoformsProteinsReportingRho-associated kinaseRoleSignal PathwaySignal TransductionSyndromeSystemic Lupus ErythematosusT-LymphocyteTestingTherapeuticTransgenic OrganismsTranslatingTreatment EfficacyTreatment Protocolsautoimmune arthritiscytokinefasudilgenetic approachinhibitor/antagonistlupus-likenovelnovel strategiesnovel therapeuticspreventpromoterresponserho GTP-Binding Proteinstherapeutic targettranscription factor
项目摘要
DESCRIPTION (provided by applicant): Rho GTPases (which include Rac and RhoA) are molecular switches that play a fundamental role in biology due to their ability to regulate both cytoskeletal dynamics and signaling pathways. Rac and RhoA target different effectors and thus regulate distinct signaling events. Rac and RhoA also cross-regulate each other since activated Rac inhibits RhoA activity and vice versa. One of the major effectors of RhoA is the Rho kinases (or ROCKs). Activation of Rho GTPases plays a key role in immune responses. Guanine nucleotide exchange factors (GEFs) are the major proteins regulating the activation of Rho GTPases. In the course of isolating proteins interacting with IRF4, a transcription factor required for the differentiation of TH-17 cells, we cloned a novel GEF that we termed IBP (IRF-4 Binding Protein), also known as Def6. Since Def6 is the official name of the gene, IBP will be hereafter referred to as Def6. Def6 is highly expressed in T cells, and, upon TCR engagement, activates Rac but not RhoA. Def6 can also be found in the nucleus where it interacts with IRF4. We previously reported that Def6-deficient mice spontaneously develop a lupus-like syndrome. We have recently found that TCR transgenic (DO11.10) Def6-deficient mice spontaneously develop RA-like arthritis. The autoimmune responses in these mice are due to an aberrant ability of CD4+ T cells to produce IL-17 and IL-21 in response to self-antigens. At a molecular level, Def6-deficient T cells exhibit defective Rac activation and an enhanced ability of IRF4 to bind to the IL-17 and IL-21 promoters. Consistent with the notion that Rac activation inhibits RhoA- induced pathways, we have recently observed that the absence of Def6 also leads to increased ROCK2 activity. Importantly, we have found that ROCK2 phosphorylates IRF4 and regulates its ability to control the production of IL-17 and IL-21. In line with these findings, Fasudil, a ROCK inhibitor, blocked the aberrant IL-17 and IL-21 production detected in the absence of Def6 and prevented development of arthritis in Def6-deficient DO11.10 mice. We now propose that the Def6-ROCK2-IRF4 axis regulates the production of IL-17 and IL-21 and that ROCK inhibitors represent a novel approach for the treatment of autoimmune arthritis. The specific goals of this proposal are: 1) To investigate the interplay between Def6 and ROCK2, 2) to delineate the role of T-cell ROCK2 in autoimmune arthritis and 3) to broadly assess the effectiveness of ROCK inhibitors in autoimmune arthritis.
描述(由申请人提供):Rho GTP酶(包括Rac和RhoA)是分子开关,由于其调节细胞骨架动力学和信号传导途径的能力,在生物学中发挥重要作用。Rac和RhoA靶向不同的效应物,从而调节不同的信号传导事件。Rac和RhoA也相互交叉调节,因为活化的Rac抑制RhoA活性,反之亦然。RhoA的主要效应物之一是Rho激酶(或ROCK)。Rho GTP酶的激活在免疫应答中起关键作用。鸟嘌呤核苷酸交换因子(GEFs)是调节Rho GTP酶活化的主要蛋白质。在分离与TH-17细胞分化所需的转录因子IRF-4相互作用的蛋白质的过程中,我们克隆了一种新的GEF,我们称之为IBP(IRF-4结合蛋白),也称为Def6。由于Def6是该基因的正式名称,因此IBP将在下文中被称为Def6。Def6在T细胞中高度表达,并且在TCR接合时激活Rac而不是RhoA。Def6也可以在细胞核中发现,在那里它与IRF4相互作用。我们以前报道,Def6缺陷小鼠自发发展狼疮样综合征。我们最近发现TCR转基因(DO11.10)Def6缺陷小鼠自发地发展RA样关节炎。这些小鼠中的自身免疫应答是由于CD4 + T细胞响应于自身抗原产生IL-17和IL-21的异常能力。在分子水平上,Def6缺陷型T细胞表现出缺陷的Rac激活和IRF4结合IL-17和IL-21启动子的能力增强。与Rac激活抑制RhoA诱导的途径的观点一致,我们最近观察到Def6的缺乏也导致ROCK 2活性增加。重要的是,我们发现ROCK 2磷酸化IRF 4并调节其控制IL-17和IL-21产生的能力。与这些发现一致,法舒地尔(一种ROCK抑制剂)阻断了在缺乏Def6的情况下检测到的异常IL-17和IL-21产生,并预防了Def6缺陷型DO11.10小鼠中关节炎的发生。我们现在提出Def6-ROCK 2-IRF4轴调节IL-17和IL-21的产生,并且ROCK抑制剂代表了治疗自身免疫性关节炎的新方法。该提案的具体目标是:1)研究Def6和ROCK 2之间的相互作用,2)描述T细胞ROCK 2在自身免疫性关节炎中的作用,3)广泛评估ROCK抑制剂在自身免疫性关节炎中的有效性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALESSANDRA B PERNIS其他文献
ALESSANDRA B PERNIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALESSANDRA B PERNIS', 18)}}的其他基金
Mechanisms controlling ABC differentiation and function in SLE
SLE 中 ABC 分化和功能的控制机制
- 批准号:
10364120 - 财政年份:2022
- 资助金额:
$ 43.88万 - 项目类别:
Mechanisms controlling ABC differentiation and function in SLE
SLE 中 ABC 分化和功能的控制机制
- 批准号:
10620619 - 财政年份:2022
- 资助金额:
$ 43.88万 - 项目类别:
Hospital for Special Surgery Research Institute Rheumatology Training
特殊外科研究所风湿科培训医院
- 批准号:
9921297 - 财政年份:2017
- 资助金额:
$ 43.88万 - 项目类别:
Regulatory Mechanisms Controlling TFH Responses in Lupus
控制狼疮 TFH 反应的调节机制
- 批准号:
9271861 - 财政年份:2016
- 资助金额:
$ 43.88万 - 项目类别:
Rho GTPase-mediated pathways in autoimmune arthritis
Rho GTPase 介导的自身免疫性关节炎通路
- 批准号:
8230157 - 财政年份:2011
- 资助金额:
$ 43.88万 - 项目类别:
相似国自然基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
- 批准号:31171277
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
- 批准号:31070748
- 批准年份:2010
- 资助金额:34.0 万元
- 项目类别:面上项目
相似海外基金
Tissue tropism of PD-1 therapy in ulcerative colitis and rheumatoid arthritis
PD-1治疗溃疡性结肠炎和类风湿性关节炎的组织向性
- 批准号:
MR/Y009681/1 - 财政年份:2024
- 资助金额:
$ 43.88万 - 项目类别:
Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
- 批准号:
MR/Y022947/1 - 财政年份:2024
- 资助金额:
$ 43.88万 - 项目类别:
Research Grant
Preclinical development of an extracellular vesicle biotherapeutic for juvenile idiopathic arthritis
幼年特发性关节炎细胞外囊泡生物治疗药物的临床前开发
- 批准号:
10068495 - 财政年份:2024
- 资助金额:
$ 43.88万 - 项目类别:
Collaborative R&D
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
- 批准号:
24K19237 - 财政年份:2024
- 资助金额:
$ 43.88万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Exploring the inflammatory mediators degraded by MMP-2 in MMP-2-deficient mice with knee arthritis through a novel TMT-TAILS quantitative proteomics
通过新型 TMT-TAILS 定量蛋白质组学探索 MMP-2 缺陷型膝关节炎小鼠中 MMP-2 降解的炎症介质
- 批准号:
24K19850 - 财政年份:2024
- 资助金额:
$ 43.88万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of an adaptive platform trial to prevent Rheumatoid Arthritis in partnership with First Nations People.
与原住民合作开发预防类风湿关节炎的适应性平台试验。
- 批准号:
491810 - 财政年份:2023
- 资助金额:
$ 43.88万 - 项目类别:
Operating Grants
The role of diet, as mediated by the gut microbiome, on childhood arthritis disease activity: a feasibility intervention study.
肠道微生物组介导的饮食对儿童关节炎疾病活动的作用:一项可行性干预研究。
- 批准号:
489316 - 财政年份:2023
- 资助金额:
$ 43.88万 - 项目类别:
Operating Grants
DEMORA: DEep spatial characterization of synovial MacrOphages in Rheumatoid Arthritis
DEMORA:类风湿性关节炎滑膜巨噬细胞的深度空间特征
- 批准号:
EP/Y027760/1 - 财政年份:2023
- 资助金额:
$ 43.88万 - 项目类别:
Fellowship
Investigation of hypoxia-inducible factor-1 (HIF-1) as a novel therapeutic target for juvenile idiopathic arthritis.
研究缺氧诱导因子-1 (HIF-1) 作为幼年特发性关节炎的新治疗靶点。
- 批准号:
23K14987 - 财政年份:2023
- 资助金额:
$ 43.88万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Novel first-in-class Therapeutics for Rheumatoid Arthritis
类风湿关节炎的一流新疗法
- 批准号:
10696749 - 财政年份:2023
- 资助金额:
$ 43.88万 - 项目类别: